Roche and Foundation Medicine, Inc. have entered into a definitive merger agreement for Roche to acquire the outstanding shares of FMI’s common stock not already owned by Roche and its affiliates at a price of $137 per share in cash. This corresponds to a total transaction value of $2.4 billion on a fully diluted basis, and…
